Product Name: (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone CAS NO:461432-22-4
Chemical & Physical Properties:
Appearance :white powder
Boiling Point:439.16℃ at 760 mmHg
Dapagliflozin works by inhibiting sodium-glucose transporter 2 (SGLT2), a protein in the kidney that allows glucose to be reabsorbed into the blood. This allows excess glucose to be eliminated from the body through urine, thereby improving blood sugar control without increasing insulin secretion. The use of this drug requires patients with normal renal function, and patients with moderate to severe renal insufficiency should not use the drug. This product alone or in combination with metformin, pioglitazone, glimepiride, insulin and other drugs can significantly reduce HbA1c and fasting blood glucose in patients with type 2 diabetes. The incidence of adverse reactions is similar to that of placebo. The risk of hypoglycemia is low and can be reduced. body weight. The efficacy of dapagliflozin is equivalent to that of several new hypoglycemic drugs such as dipeptidyl peptidase inhibitors, and it can slightly lower blood pressure and weight.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.